← Eichor
Study identifier: NCT04900623 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Condition: HPV-Associated Oropharyngeal Squamous Cell Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage  ·  Sponsor: Jonathan Schoenfeld, MD, MPH

PhasePhase 2
Planned participants145
Who can joinAll sexes, 22 Years to no upper limit
Healthy volunteersNo

About this study

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: * NavDx® HPV ctDNA testing (HPV blood test) * Radiation therapy * Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

This description comes directly from the study's public registry record.

Talk to the study team

Jonathan Schoenfeld, MD, MPH  ·  617-632-3591  ·  jonathan_schoenfeld@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04900623